The current NCCN guidelines state that “FSH and estradiol should be repeated serially to ensure menopausal status in patients with breast cancer with chemotherapy-induced amenorrhea.”[4] NCCN guidelines also recommend assessment ovarian function “prior to next dose of GnRH agonist especially in women younger than 45 years with frequency of testing individualized” and current ASCO guidelines alert clinicians about the risk of incomplete ovarian suppression with GnRHa and recommend evaluation of patients at risk for residual ovarian function [3]. The gene discussed is GNRH1; the disease is breast cancer.